<p>在美国制药行业，市销率（&#34;P/S&#34;）的中位数接近 3.5 倍，因此你可能会对 <strong>Prestige Consumer Healthcare Inc.</strong>（纽约证券交易所代码：PBH）3.6 倍的市销率感到无所谓。虽然这可能不会引起任何人的注意，但如果市销率没有合理的依据，投资者可能会错过潜在的机会或忽视即将到来的失望。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前入场。</p>
<p>查看我们对 Prestige Consumer Healthcare 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/10969688-ps-multiple-vs-industry-1-dark/1744811090815?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/10969688-ps-multiple-vs-industry-1-dark/1744811090815"/></p>
<p>纽约证券交易所：PBH 市销率与行业对比 2025 年 4 月 16 日</p>
<h3>Prestige Consumer Healthcare 的市销率对股东意味着什么？</h3>
<p>Prestige Consumer Healthcare 的表现可能更好，因为其收入最近一直在下降，而大多数其他公司则在实现正增长。可能许多人期望其低迷的收入表现会有所改善，这使得市销率没有下滑。你真的希望如此，否则你将为这样一种增长模式的公司支付相对较高的价格。</p>
<p>想要了解分析师对公司的完整估计吗？那么我们 <strong>免费的</strong>Prestige Consumer Healthcare 报告将帮助你揭示未来的趋势。</p>
<h2>Prestige Consumer Healthcare 的收入增长趋势如何？</h2>
<p>为了证明其市销率的合理性，Prestige Consumer Healthcare 需要实现与行业相似的增长。</p>
<p>回顾过去一年，公司收入出现了令人沮丧的 1.4% 的下降。这对其长期以来的良好表现造成了影响，因为其三年总收入增长仍然值得注意，达到了 5.7%。因此，我们可以确认，公司在这段时间内总体上做得很好，尽管在此过程中遇到了一些波折。</p>
<p>展望未来，预计未来三年每年将实现 2.4% 的增长，这是八位分析师对公司的估计。考虑到行业预计每年将实现 20% 的增长，公司面临较弱的收入结果。</p>
<p>根据这些信息，我们发现 Prestige Consumer Healthcare 的市销率与行业相对接近，这很有趣。似乎大多数投资者忽视了相对有限的增长预期，并愿意为接触该股票支付更高的价格。维持这些价格将是困难的，因为这种收入增长水平可能最终会对股价造成压力。</p>
<h2>我们可以从 Prestige Consumer Healthcare 的市销率中学到什么？</h2>
<p>我们认为市销率的作用并不主要作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
<p>考虑到 Prestige Consumer Healthcare 的收入增长预期相对较低，与更广泛的行业相比，看到其以当前市销率交易令人感到意外。当我们看到与行业相比收入前景相对较弱的公司时，我们怀疑股价面临下跌的风险，从而使适度的市销率降低。这样的情况对当前和潜在投资者构成风险，如果低收入增长影响情绪，股价可能会下跌。</p>
<p>话虽如此，请注意 <strong>Prestige Consumer Healthcare 在我们的投资分析中显示出 1 个警告信号</strong>，你应该了解。</p>
<p><strong>如果你对过去盈利增长稳健的公司感兴趣</strong>，你可能希望查看这份 <strong>免费的</strong> 其他盈利增长强劲且市盈率低的公司集合。</p>
<p>如果你打算交易 Prestige Consumer Healthcare，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
<p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让你可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
<p>享受无隐藏费用、无账户最低限额，以及低至 0.03% 的外汇转换率，远远优于大多数经纪商提供的服务。</p>
<p>赞助内容</p>

普雷斯蒂奇

<p>普雷斯蒂奇消费医疗公司（NYSE:PBH）的市销率为 3.6 倍，略高于行业中位数 3.5 倍。尽管最近收入下降了 1.4%，分析师预计未来三年将实现温和的 2.4% 增长，远低于行业预期的 20% 增长。这一差异引发了对其当前市销率可持续性的担忧，暗示如果收入增长没有改善，投资者可能面临风险。该公司目前的估值可能未能反映其低迷的增长前景，表明股价下跌的风险</p>

<p>With a median price-to-sales (or &#34;P/S&#34;) ratio of close to 3.5x in the Pharmaceuticals industry in the United States, you could be forgiven for feeling indifferent about <strong>Prestige Consumer Healthcare Inc.'s</strong> (NYSE:PBH) P/S ratio of 3.6x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.</p>
<div class="lb-trans"><p>在美国制药行业，市销率（&#34;P/S&#34;）的中位数接近 3.5 倍，因此你可能会对 <strong>Prestige Consumer Healthcare Inc.</strong>（纽约证券交易所代码：PBH）3.6 倍的市销率感到无所谓。虽然这可能不会引起任何人的注意，但如果市销率没有合理的依据，投资者可能会错过潜在的机会或忽视即将到来的失望。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前入场。</p>
</div><p>View our latest analysis for Prestige Consumer Healthcare</p>
<div class="lb-trans"><p>查看我们对 Prestige Consumer Healthcare 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/10969688-ps-multiple-vs-industry-1-dark/1744811090815" alt="" original-src="https://images.simplywall.st/asset/chart/10969688-ps-multiple-vs-industry-1-dark/1744811090815"/></p>
<p>NYSE:PBH Price to Sales Ratio vs Industry April 16th 2025</p>
<div class="lb-trans"><p>纽约证券交易所：PBH 市销率与行业对比 2025 年 4 月 16 日</p>
</div><h3>What Does Prestige Consumer Healthcare's P/S Mean For Shareholders?</h3>
<div class="lb-trans"><h3>Prestige Consumer Healthcare 的市销率对股东意味着什么？</h3>
</div><p>Prestige Consumer Healthcare could be doing better as its revenue has been going backwards lately while most other companies have been seeing positive revenue growth. It might be that many expect the dour revenue performance to strengthen positively, which has kept the P/S from falling. You'd really hope so, otherwise you're paying a relatively elevated price for a company with this sort of growth profile.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare 的表现可能更好，因为其收入最近一直在下降，而大多数其他公司则在实现正增长。可能许多人期望其低迷的收入表现会有所改善，这使得市销率没有下滑。你真的希望如此，否则你将为这样一种增长模式的公司支付相对较高的价格。</p>
</div><p>Want the full picture on analyst estimates for the company? Then our <strong>free</strong> report on Prestige Consumer Healthcare will help you uncover what's on the horizon.</p>
<div class="lb-trans"><p>想要了解分析师对公司的完整估计吗？那么我们 <strong>免费的</strong>Prestige Consumer Healthcare 报告将帮助你揭示未来的趋势。</p>
</div><h2>How Is Prestige Consumer Healthcare's Revenue Growth Trending?</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 的收入增长趋势如何？</h2>
</div><p>In order to justify its P/S ratio, Prestige Consumer Healthcare would need to produce growth that's similar to the industry.</p>
<div class="lb-trans"><p>为了证明其市销率的合理性，Prestige Consumer Healthcare 需要实现与行业相似的增长。</p>
</div><p>Retrospectively, the last year delivered a frustrating 1.4% decrease to the company's top line. That put a dampener on the good run it was having over the longer-term as its three-year revenue growth is still a noteworthy 5.7% in total. So we can start by confirming that the company has generally done a good job of growing revenue over that time, even though it had some hiccups along the way.</p>
<div class="lb-trans"><p>回顾过去一年，公司收入出现了令人沮丧的 1.4% 的下降。这对其长期以来的良好表现造成了影响，因为其三年总收入增长仍然值得注意，达到了 5.7%。因此，我们可以确认，公司在这段时间内总体上做得很好，尽管在此过程中遇到了一些波折。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 2.4% each year as estimated by the eight analysts watching the company. With the industry predicted to deliver 20% growth each year, the company is positioned for a weaker revenue result.</p>
<div class="lb-trans"><p>展望未来，预计未来三年每年将实现 2.4% 的增长，这是八位分析师对公司的估计。考虑到行业预计每年将实现 20% 的增长，公司面临较弱的收入结果。</p>
</div><p>With this information, we find it interesting that Prestige Consumer Healthcare is trading at a fairly similar P/S compared to the industry. It seems most investors are ignoring the fairly limited growth expectations and are willing to pay up for exposure to the stock. Maintaining these prices will be difficult to achieve as this level of revenue growth is likely to weigh down the shares eventually.</p>
<div class="lb-trans"><p>根据这些信息，我们发现 Prestige Consumer Healthcare 的市销率与行业相对接近，这很有趣。似乎大多数投资者忽视了相对有限的增长预期，并愿意为接触该股票支付更高的价格。维持这些价格将是困难的，因为这种收入增长水平可能最终会对股价造成压力。</p>
</div><h2>What We Can Learn From Prestige Consumer Healthcare's P/S?</h2>
<div class="lb-trans"><h2>我们可以从 Prestige Consumer Healthcare 的市销率中学到什么？</h2>
</div><p>We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>我们认为市销率的作用并不主要作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
</div><p>Given that Prestige Consumer Healthcare's revenue growth projections are relatively subdued in comparison to the wider industry, it comes as a surprise to see it trading at its current P/S ratio. When we see companies with a relatively weaker revenue outlook compared to the industry, we suspect the share price is at risk of declining, sending the moderate P/S lower. Circumstances like this present a risk to current and prospective investors who may see share prices fall if the low revenue growth impacts the sentiment.</p>
<div class="lb-trans"><p>考虑到 Prestige Consumer Healthcare 的收入增长预期相对较低，与更广泛的行业相比，看到其以当前市销率交易令人感到意外。当我们看到与行业相比收入前景相对较弱的公司时，我们怀疑股价面临下跌的风险，从而使适度的市销率降低。这样的情况对当前和潜在投资者构成风险，如果低收入增长影响情绪，股价可能会下跌。</p>
</div><p>Having said that, be aware <strong>Prestige Consumer Healthcare is showing 1 warning sign</strong> in our investment analysis, you should know about.</p>
<div class="lb-trans"><p>话虽如此，请注意 <strong>Prestige Consumer Healthcare 在我们的投资分析中显示出 1 个警告信号</strong>，你应该了解。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果你对过去盈利增长稳健的公司感兴趣</strong>，你可能希望查看这份 <strong>免费的</strong> 其他盈利增长强劲且市盈率低的公司集合。</p>
</div><p>If you're looking to trade Prestige Consumer Healthcare, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果你打算交易 Prestige Consumer Healthcare，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让你可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受无隐藏费用、无账户最低限额，以及低至 0.03% 的外汇转换率，远远优于大多数经纪商提供的服务。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>赞助内容</p>
</div>

普雷斯蒂奇消费者健康公司（NYSE:PBH）的投资者没有预期的那么悲观